aminosalicylic acid
Trade name: Paser
Approved
Mar 8, 1950
Aminosalicylic acid can refer to any amino derivative of salicylic acid, such as:3-Aminosalicylic acid 4-Aminosalicylic acid 5-Aminosalicylic acid (mesalazine) 6-Aminosalicylic acid — Wikipedia
Clinical trial activity
20 trials · 32 clinical orgs · 12 marketing orgs
Earliest trial started Dec 1, 1995 (NCT00004423)
Timeline
1950s
- Mar 8, 1950
Earliest FDA Approval
- Mar 8, 1950
Consolidated Midland — NDA Secondary Org
- Nov 18, 1955
Glenwood Pharmaceuticals — NDA Secondary Org
1970s
- Apr 14, 1971
Hexcel — Marketing Organization
- Aug 12, 1975
Medpointe — Marketing Organization
- Jan 17, 1978
Lannett Company, Inc. — Marketing Organization
1990s
- Jun 30, 1994
Jacobus Pharmaceutical — Marketing Organization
- Jun 30, 1994
EUROCEPT PHARMS — Marketing Organization
- Jun 30, 1994
Adaptis Pharma — Marketing Organization
- Jan 1, 1996
Earliest Phase 2 Sponsor(trial)
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
2000s
- Jan 1, 2007
Earliest Phase 3 Sponsor(trial)
Indications
Approved for
Studied for
- Colitis, Ulcerative · Phase 2
- Crohn Disease · Phase 2
- Fecal Microbiota Transplantation · Phase 2/Phase 3
- Healthy Volunteers · Phase 1
- HIV Infections · Phase 4
- Inflammatory Bowel Diseases · Phase 4
- Sleep Apnea Syndromes · Phase 1/Phase 2
- Tuberculosis · Phase 3
- Tuberculosis, Multidrug-Resistant · Phase 2
- Tuberculosis, Pulmonary · Phase 3
Mechanism of action
- Dihydrofolate reductaseINHIBITOR
folA inhibitor
PAS is incorporated into the folate pathway by dihydropteroate synthase (DHPS) and dihydrofolate synthase (DHFS) to generate a hydroxyl dihydrofolate antimetabolite, which in turn inhibits DHFR enzymatic activity.
- CyclooxygenaseINHIBITOR
Cyclooxygenase inhibitor
Approval history
- approvedMar 8, 1950
Chemistry & pharmacology
SMILES
Nc1ccc(C(=O)O)c(O)c1- Mol. weight
- 153.14 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaAminosalicylic acid ↗
- ChEMBLCHEMBL1200966 ↗
- ChEMBLCHEMBL1200584 ↗
- ChEMBLCHEMBL2096646 ↗
- NCATS7N21461LKD ↗
- NCATS5B2658E0N2 ↗
- ChEMBLCHEMBL1169 ↗
Also known as
- 4-amino-2-hydroxybenzoic acid
- 4-amino-2-hydroxybenzoic acid
- 4-aminosalicylate
- 4-aminosalicylate
- 4-aminosalicylic acid
- 4-aminosalicylic acid
- 4-aminosalicylic acid
- 4-aminosalicylic acid
- 4-aminosalicylic acid
- 4-aminosalicylic acid
- 4-carboxy-3-hydroxyaniline
- 5-aminosalicylate
- 5-aminosalicylate
- aminosalicylate
- aminosalicylate
- aminosalicylate potassium
- aminosalicylate potassium
- aminosalicylate potassium
- aminosalicylate sodium
- aminosalicylate sodium
- aminosalicylate sodium
- aminosalicylate sodium
- aminosalicylic acid
- aminosalicylic acid
- aminosalicylic acid
- aminosalicylic acid
- aminosalicylic acid
- aminosalicylic acid
- aminosalicylic acid
- aminosalicylic acid
- aminosalicylic acid resin complex
- aminosalicylic acid resin complex
- aminosalicylic acid resin complex
- aminosalicylic acid resin complex
- aminosalicylic acid resin complex
- aminosalicylic acid resin complex
- aminosalicylic acid resin complex
- aminosalyle sodium
- aminosalyle sodium
- apacil
- granupas
- p-aminosalicylic acid
- p-aminosalicylic acid
- p-aminosalicylic acid
- para-amino salicylic acid
- para-amino salicylic acid
- para-aminosalicylic acid
- para-aminosalicylic acid
- para-aminosalicylic acid
- para-aminosalicylic acid
- para-aminosalicylic acid
- para-aminosalicylic acid
- parasal
- parasal
- parasal
- parasal sodium
- parasal sodium
- pas
- pas
- pas
- paser
- paser
- paskalium
- paskalium
- p.a.s. sodium
- p.a.s. sodium
- potassium aminosalicylate
- potassium aminosalicylate
- potassium aminosalicylate
- potassium aminosalicylate
- rezipas
- rezipas
- sodium aminosalicylate
- sodium aminosalicylate
- sodium aminosalicylate
- sodium aminosalicylate
- sodium p.a.s.
- sodium p.a.s.
- teebacin
- teebacin
- teebacin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06081361 | Phase 3 | Nov 1, 2023 | Capital Medical University |
| NCT03892772 | Phase 1/Phase 2 (Phase 2) | Apr 15, 2019 | Harvard University |
| NCT03804931 | Phase 2/Phase 3 (Phase 3) | Jan 20, 2019 | Guangzhou Medical University |
| NCT02975570 | Phase 3 | Aug 1, 2017 | Boston University, University of Florida, Westat |
| NCT03070405 | Phase 1 | Oct 1, 2016 | Inje University |
| NCT02354014 | Phase 2 | May 3, 2016 | Johnson and Johnson |
| NCT02683733 | Phase 3 | Feb 1, 2016 | Asian Institute of Gastroenterology, Asian Institutes of Gastroenterology |
| NCT02665845 | Phase 3 | Feb 1, 2016 | University of Lyon |
| NCT02365623 | Phase 2 | Feb 18, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
| NCT01320436 | Phase 3 | Jul 1, 2011 | Tel Aviv University |
| NCT00984568 | Phase 3 | Nov 1, 2009 | Merck |
| NCT00603733 | Phase 3 | Oct 1, 2007 | Ferring |
| NCT00495521 | Phase 2 | Jun 1, 2007 | Atlantic Health System, Baylor University, Cedars-Sinai Medical Center, Children's Center for Digestive Healthcare, LLC, Atlanta, Georgia, USA, Jacobus Pharmaceutical, University of California, San Francisco |
| NCT00417690 | Phase 2 | Jan 1, 2007 | Charlotte Gastroenterology & Hepatology, PLLC, Icahn School of Medicine at Mount Sinai, Jacobus Pharmaceutical, Technion University, Tel Aviv University, University of Chicago |
| NCT00167882 | Phase 4 | Jul 1, 2005 | Free University of Amsterdam, University of Amsterdam |
| NCT00042289 | Phase 4 | Mar 1, 2003 | Boston University, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT00000796 | N/A | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00069498 | Phase 1 | Oct 1, 1999 | National Institute of Allergy and Infectious Diseases (NIAID), University of California, Los Angeles |
| NCT00004810 | Phase 2 | Jun 1, 1996 | National Center for Research Resources (NCRR), University of Vermont |
| NCT00004423 | N/A | Dec 1, 1995 | University of Vermont |
Organizations
Research & Development (32)
Marketing (12)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Adaptis Pharma | For profit | MKTG | Jun 30, 1994 |
| Bristol-Myers Squibb | For profit | NDA2 | — |
| Century Pharmaceuticals | For profit | MKTG | — |
| Ciba | For profit | NDA | — |
| Consolidated Midland | For profit | NDA2 | Mar 8, 1950 |
| EUROCEPT PHARMS | For profit | MKTG | Jun 30, 1994 |
| Glenwood Pharmaceuticals | For profit | NDA2 | Nov 18, 1955 |
| Hexcel | For profit | MKTG | Apr 14, 1971 |
| Jacobus Pharmaceutical | For profit | MKTG | Jun 30, 1994 |
| Lannett Company, Inc. | For profit | MKTG | Jan 17, 1978 |
| Medpointe | For profit | MKTG | Aug 12, 1975 |
| Panray Corp. | For profit | NDA2 | — |